Induction of M2 regulatory macrophages through the β2- Adrenergic receptor with protection during endotoxemia and acute lung injury

Journal of Innate Immunity

Volumn 6, Issue 5, 2014, Pages 607-618

  Grailer, Jamison J ^a   Haggadone, Mikel D ^a   Sarma, J Vidya ^a   Zetoune, Firas S ^a   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Catecholamines; Cytokines; Inflammation; Macrophages

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ADRENALIN; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 3A ADRENERGIC RECEPTOR; ARGINASE 1; BETA 2 ADRENERGIC RECEPTOR; CATECHOLAMINE; CXCL1 CHEMOKINE; CXCL3 CHEMOKINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NORADRENALIN; PHOSPHATIDYLINOSITOL 3 KINASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYCLIC AMP; EPINEPHRINE;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CELL PROTECTION; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOTOXEMIA; LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA; LYMPHOCYTE ACTIVATION; M2 MACROPHAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL; INFLAMMATION; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; DISEASE MODEL; HUMAN; IMMUNOLOGY; MACROPHAGE ACTIVATION; METABOLISM; TH2 CELL;

ACUTE LUNG INJURY; ANIMALS; CATECHOLAMINES; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; EPINEPHRINE; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NOREPINEPHRINE; PHAGOCYTOSIS; PHENOTYPE; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; TH2 CELLS;

EID: 84906938319     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000358524     Document Type: Article

References (39)

1. Mosser DM, Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
2. Lawrence T, Natoli G: Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011; 11: 750-761.
3. Murray PJ, Wynn TA: Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11: 723-737.
4. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
5. Barron L, Wynn TA: Fibrosis is regulated by Th2 and Th17 responses and by dynami c interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol 2011; 300:G723-G728.
6. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, Smith AM, Thompson RW, Cheever AW, Murray PJ, Wynn TA: Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 2009; 5:e1000371.
7. Munder M: Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 2009; 158: 638-651.
8. Kroncke KD, Fehsel K, Kolb-Bachofen V: Inducible nitric oxide synthase and its product nitric oxide, a sma ll molecule with complex biological activities. Biol Chem Hoppe Seyler 1995; 376: 327-343.
9. Morris SM Jr: Arginine metabolism: boundaries of our knowledge. J Nutr 2007; 137: 1602S-1609S.
10. Martinez FO, Sica A, Mantovani A, Locati M: Macrophage activation and polarization. Front Biosci 2008; 13: 453-461.
11. Stein M, Keshav S, Harris N, Gordon S: Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287-292.
12. Edwards JP, Zhang X, Frauwirth KA, Mosser DM: Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 2006; 80: 1298-1307.
13. Spengler RN, Chensue SW, Giacherio DA, Blenk N, Kunkel SL: Endogenous norepinephrine regulates tumor necrosis factor-α production from macrophages in vitro. J Immunol 1994; 152: 3024-3031.
14. Huang JL, Zhang YL, Wang CC, Zhou JR, Ma Q, Wang X, Shen XH, Jiang CL: Enhanced phosphorylation of MAPKs by NE promotes TNF-α production by macrophage throug h α adrenergic receptor. Inflammation 2012; 35: 527-534.
15. Bosmann M, Grailer JJ, Zhu K, Matthay MA, Sarma JV, Zetoune FS, Ward PA: Anti-inflammatory effects of β2 adrene rgic receptor agonists in experimental acute lung injury. FASEB J 2012; 26: 2137-2144.
16. Donnelly LE, Tudhope SJ, Fenwick PS, Barnes PJ: Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages. Eur Respir J 2010; 36: 178-186.
17. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J: M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than M1 cells in vitro. J Immunol 2009; 182: 4415-4422.
18. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS: CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 2007; 104: 19446-19451.
19. Rey-Giraud F, Hafner M, Ries CH: In vitro generation of monocyte-derived macrophages under serum-free conditions improves their tumor promoting functions. PLoS One 2012; 7:e42656.
20. Anderson CF, Mosser DM: A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol 2002; 72: 101-106.
21. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, McGuire SR, List RP, Day DE , Hoesel LM, Gao H, Van Rooijen N, Huber-Lang MS, Neubig RR, Ward PA: Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 2007; 449: 721-725.
22. Bond RA, Le ff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF, Lefkowitz RJ: Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the b eta 2-adrenoceptor. Nature 1995; 374: 272-276.
23. Gregg CJ, Steppan J, Gonzalez DR, Champion HC, Phan AC, Nyhan D, Shoukas AA, Hare JM, Barouch LA, Berkowitz DE: β2-Ad renergic receptor-coupled phosphoinositide 3-kinase constrains camp-dependent increases in cardiac inotropy through phosphodiesterase 4 activation. Anesth Analg 2010; 111: 870-877.
24. Murray DR, Mummidi S, Valente AJ, Yoshida T, Somanna NK, Delafontaine P, Dinarello CA, Chandrasekar B: β2 Adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrop hy in vitro and myocardial hypertrophy in vivo. J Mol Cell Cardiol 2012; 52: 206-218.
25. van der Poll T, Jansen J, Endert E, Sauerwein HP, van Deventer SJ: Noradrenaline inhibits lipopolysacc haride-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect Immun 1994; 62: 2046-2050.
26. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epineph rine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996; 97: 713-719.
27. van der Poll T, Lowry SF: Epinephrine inhibits endotoxin-induced IL-1 beta production: roles of tumor necrosis factor-alpha and IL-10. Am J Physiol 1997; 273:R1885-R1890.
28. Lin Y, Zhu X, Yao WZ, Yang YL, A LT, Chen L: Yohimbine protects against endotoxin-induced acute lung injury by blockade of alpha 2a adrenergic receptor in rats. Chin Med J 2011; 124: 1069-1074.
29. Fernandez S, Jose P, Avdiushko MG, Kaplan AM, Cohen DA: Inhibition of IL-10 receptor function in alveolar macrophages by Toll-like receptor agonists. J Immunol 2004; 172: 2613-2620.
30. Zhang X, Majlessi L, Deriaud E, Leclerc C, Lo-Man R: Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 2009; 31: 761-771.
31. Nelms K , Keegan AD, Zamorano J, Ryan JJ, Paul WE: The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17: 701-738.
32. Whyte CS, Bishop ET, Ruckerl D, G aspar-Pereira S, Barker RN, Allen JE, Rees AJ, Wilson HM: Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J Leukoc Biol 2011; 90: 845-854.
33. Mac Kinnon AC,Farnworth SL,Hodkinson PS,Henderson NC,Atkinson KM,Leffler H,Nilsson UJ,Haslett C,Forbes SJ,Sethi T: Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008; 180: 2650-2658.
34. Rauh MJ, Ho V, Pereira C, Sham A, Sly LM, Lam V, Huxham L, Minchinton AI, Mui A, Krystal G: Ship represses the generation of alternatively activated m acrophages. Immunity 2005; 23: 361-374.
35. Strassmann G, Patil-Koota V, Finkelman F, Fong M, Kambayashi T: Evidence for the involvement of interleukin 10 in the differential deactivation of m urine peritoneal macrophages by prostaglandin E2. J Exp Med 1994; 180: 2365-2370.
36. Hasko G, Pacher P, Deitch EA, Vizi ES: Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther 2007; 113: 264-275.
37. Sternberg EM: Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 2006; 6: 318-328.
38. Franchimont D: Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NY Acad Sci 2004; 1024: 124-137.
39. Mesotten D, Vanhorebeek I, Van den Bergh G: The altered adrenal axis and treatment with glucocorticoids during critical illness. Nat Clin Pract Endocrinol Metab 2008; 4: 496-505.